Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance.
about
Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis.Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells.Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivoRisk prediction model for epithelial ovarian cancer using molecular markers and clinical characteristics.The role of natural killer cells in immunity against multiple myeloma.Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy.Mutant KRAS Enhances Tumor Cell Fitness by Upregulating Stress Granules.Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche.Celecoxib enhances the anti-inflammatory effects of farnesylthiosalicylic acid on T cells independent of prostaglandin E(2) production.The molecular mechanisms of chemoresistance in cancers.Thalidomide and its analogues: A review of the potential for immunomodulation of fibrosis diseases and opthalmopathy.An integrated bioinformatical analysis of miR-19a target genes in multiple myeloma.
P2860
Q27692033-DFC01DEC-B0F4-4756-B95B-E245604213E4Q33748979-4202142E-73B4-4C0E-9D67-284E1CBD2A97Q35859205-E3D5A08F-114B-4785-BF5E-C1127CDF3A76Q36162685-C4B68192-F7FE-4965-9D3C-1E8E2E687A5FQ36199823-1A968C23-AFA3-4F95-8E24-3BD2C0CBB9B8Q37994234-539D6391-3F34-4D9E-87AD-74A5A14592C2Q38074017-7DD3130D-07D8-4FE6-B7F8-531E862EB348Q38725826-2A104690-CC85-4ADA-A4A8-126EA8934092Q38932298-A6440340-788B-40A7-AEDD-8C3BE04431E5Q39333052-4290DAF3-2F1B-4990-A56A-2ADCA3802B41Q41709101-828CDC71-FD4F-4C10-83DF-4671B48E642FQ47096268-6B73CE52-94D4-4A2D-BB94-6A5016DAF237Q47100075-BB7DE13C-A47C-4751-9A39-A1514D589286
P2860
Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Oncogenic RAS mutations in mye ...... bronectin and chemoresistance.
@en
type
label
Oncogenic RAS mutations in mye ...... bronectin and chemoresistance.
@en
prefLabel
Oncogenic RAS mutations in mye ...... bronectin and chemoresistance.
@en
P2093
P2860
P1433
P1476
Oncogenic RAS mutations in mye ...... ibronectin and chemoresistance
@en
P2093
Alan Lichtenstein
Huajun Yan
Lee Goodglick
Sanjai Sharma
Sherven Sharma
Steven Dubinett
Yijiang Shi
P2860
P304
P356
10.1182/BLOOD-2005-09-3926
P407
P577
2006-02-23T00:00:00Z